Anti-Human CD40 [Clone G28.5] — Purifiedin vivoPLATINUM™ Functional Grade,Leinco,C8205

Host

Mouse

Reactivity

Human

Application

FA,FC,in vivo

Platform ID

BAB822035561

Leinco

Headquarters

410 Axminister Drive St. Louis, Missouri 63026

Contact

Tel: +1 (800) 538-1145,+1 (636) 230-9477
Fax:

Product Specifications
Scientific Background

Specifications

NameAnti-Human CD40 [Clone G28.5] — Purifiedin vivoPLATINUM™ Functional Grade
Cat. No.C8205
HostMouse
ReactivityHuman
ApplicationFA,FC,in vivo
Clone NumberG28.5
Purity≥98% monomer by analytical SEC ⋅ >95% by SDS Page
Endotoxin Level<0.5 EU/mg as determined by the LAL method
ShippingNext Day 2-8°C
FormulationThis monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
StorageFunctional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Scientific Background

CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.